Skip to main content
    N

    Neuropace Inc (NPCE)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $7.97
    +0.41 (+5.42%)

    Market Cap: $260.45M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Neuropace Inc (NPCE) Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Neuropace (NPCE) trades at 2.9x sales and 23.8x book value. Its P/S of 2.9x is below its 5-year median of 3.8x. Its forward P/E is 84.0x.

    Current Multiples

    MultipleValue
    P/E (trailing)N/A
    Forward P/E84.0x
    Price to sales2.9x
    Price to book23.8x
    PEGN/A
    FCF yield-4.5%
    As of Nov 17, 2026

    Historical Medians

    MultipleCurrent5-year median10-year median
    P/S2.9x3.8xN/A
    P/B23.8x15.7xN/A
    Medians of month-end values through Oct 2026: 60 months (5-year).

    Valuation History

    Over the 5 year ends shown, its P/S ranged from 0.2x in 2021 to 5.5x in 2025. 2025 was the highest of those years.

    Year endPriceP/SP/B
    2025$15.445.5x26.5x
    2024$11.194.1x41.8x
    2023$10.314.0x12.9x
    2022$1.490.8x1.1x
    2021$10.080.2x3.3x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported.

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About NPCE

    What is NPCE's forward P/E ratio?

    Neuropace has a forward P/E ratio of 84.0x.

    Is NPCE stock overvalued?

    GNG's valuation label for NPCE is Undervalued.

    What is NPCE's price to sales ratio?

    Neuropace has a price to sales ratio of 2.9x.